EMBO Molecular Medicine is an open access online journal published by EMBO Press.
The quality of the journal is guaranteed by the editorial and advisory boards, consisting of leading researchers in the field of molecular medicine, together with the commitment to scientific excellence and the professionalism of EMBO Editors.
|Chief Editor||Philippe Sansonetti|
|Senior Editors||Dario Alessi
Bart de Strooper
|EMBO Editors||Roberto Buccione
Aims and scope
EMBO Molecular Medicine is a peer-reviewed, online open access journal dedicated to a new research discipline at the interface between clinical research and basic biology. It offers clinicians and researchers in this area the opportunity to publish their best work in a broadly distributed and highly visible forum, thereby lending a strong impetus to this important and rapidly developing field and helping to forge new links between clinicians and molecular biologists. Studies based on model organisms also fall within the scope of the journal, provided that the results presented are evidently and directly relevant to human disease.
EMBO Molecular Medicine publishes research articles as full-length research papers and short reports. In addition, the journal publishes editorials and review articles in innovative formats that target a broad and non-specialized audience.
Areas within the scope include, but are not limited to:
Differentiation and development
Genomics, transcriptomics, proteomics, metabolomics of disease, systems medicine
Immunology and inflammation
Neurodegeneration, neurological diseases and myopathies, sensory defects
Stem cells and regenerative medicine
Vascular and cardiovascular biology
Citing EMBO Molecular Medicine Articles
EMBO Molecular Medicine articles are cited according to their full article identifier as follows:
Morais VA, Verstreken P, Roethig A, Smet J, Snellinx A, Vanbrabant M, Haddad D, Frezza C, Mandemakers W, Vogt-Weisenhorn D, Van Coster R, Wurst W, Scorrano L, De Strooper B (2009) Parkinson's disease mutations in PINK1 result in decreased complex I activity and deficient synaptic function. EMBO Mol Med 1: 99-111
molecular biologists, clinicians and medical doctors
Transparent Editorial Process
EMBO Molecular Medicine has a fair and transparent process to rapidly publish important science.
- No confidential referee remarks
- Published anonymous referee reports and editorial correspondence
- Editors respect requests to exclude specific referees
- Editors justify editorial decisions in detail and specify what is required for a revision
- No journal-specific formatting required at submission; manuscripts are assessed for science, not for style
- Similar findings that are published by others during review or revision are not a criterion for rejection
- In exceptional circumstances, editors may consider manuscripts that have just been scooped
- Referees are invited to comment on each other's reports before the editor makes a decision, ensuring a balanced review process
- Papers rarely undergo more than one major round of revision
- Referees are asked to focus on essential revisions and to consider the feasibility of experiments they suggest
- Revisions are invited only if they are possible in a realistic time frame
- Editors ensure that referees do not raise new non-essential points upon revision
- More than 90% of invited revisions are published at EMBO Molecular Medicine
- Editorial decisions are returned within a week and referee comments in less than a month
- After acceptance, we can publish fully edited papers within 10 days
- Authors can discuss manuscripts with editors at any stage in the process, including during revision and following rejection. Editors may invite author feedback on referee reports before reaching a decision
- Scientific editors undertake a comprehensive evaluation of each manuscript. Editorial board members advise rapidly on manuscripts
- Authors are encouraged to publish the unprocessed source data underlying graphs, gels and micrographs alongside the figures to promote data transparency and reuse
- Supplementary information is restricted to essential data supporting key claims in the main paper. Structured datasets, models and detailed protocols are also permitted
- Authors can elect to transfer manuscripts with referee reports between the EMBO publications. Editors prioritize transfers and base decisions on the available information, ensuring exceptional manuscripts can be published without delay
|Impact Factor (2015): 9.5 (Thomson Reuters)
5-year Impact Factor (2015): 9.5 (Thomson Reuters)
Immediacy Index (2015): 2.0 (Thomson Reuters)
Eigenfactor (2015): 0.02 (eigenfactor.org)
Article Influence (2015): 3.7 (eigenfactor.org)
SJR (2014): 4.1 (JournalM3trics)
SNIP (2014): 1.6 (JournalM3trics)
h5 (2011-2015): 60 (Google Scholar)
EMBO Molecular Medicine encourages applying due care in interpreting these numbers. EMBO Press is a foundation signatory of the San Francisco Declaration on Research Assessment (DORA) pointing to flaws in the Journal Impact Factor and particular in its application to the assessment of the research output of individuals. Please read this editorial for a more detailed discussion [The EMBO Journal (2015) 34, 1601-1602].
Citations in 2015 to research papers and reviews published in 2013 or 2014.
Median = 6, mean = 8.6
Open Access and Charges
EMBO Molecular Medicine levies an Article Processing Charge (APC) of 3,300 EUROS (4,200 USD/GBP 2,750) for each Research Article or Report accepted for publication. There are no additional costs (such as page charges or submission charges).
No charges apply for Reviews, Closeups, Perspectives, Bridge the Gap or Correspondences.
At revision stage, authors are prompted by the system to fill in their funding and payment details.
We will automatically waive or discount charges for corresponding authors working in countries covered by the Research4Life Initiative (see the Wiley Open Access Waiver Country List). In exceptional circumstances charges may be reduced for authors who can provide evidence that they are unable to pay the fees.
Upon acceptance, the corresponding author will receive instructions by email for completing the relevant license forms.
Processing of an accepted manuscript for publication can only proceed once the funding and payment details have been provided via the system and the licence to publish has been returned.
Authors who receive funding from an agency or institution with a Wiley Open Access Account do not pay directly - the charge is paid by the institution or funder. Authors whose institutions have paid the Wiley Open Access partner fee are eligible for a discount on the publication charge - on acceptance a discounted fee is payable by the author. Please see additional details on the online payment page when you submit your revised manuscript.
EMBO Molecular Medicine articles are freely accessible to all via the Internet and are also deposited immediately upon publication, without embargo, to the Open Access repository PubMed Central.
Copyright on any article published by EMBO Molecular Medicine is retained by the author(s).
EMBO Molecular Medicine articles are published under the Attribution 3.0 Unported (CC BY 3.0) Creative Commons License. This license permits users to access, download, copy, display and redistribute EMBO Molecular Medicine articles, as well as adapt, translate, text- and data-mine the content subject to the following conditions:
- The authors' moral rights are not compromised. These rights include the right of "paternity" (also known as "attribution" - the right for the author to be identified as such) and "integrity" (the right for the author not to have the work altered in such a way that the author's reputation or integrity may be impugned).
- If article content is copied, downloaded or otherwise reused, a link to the appropriate bibliographic citation (authors, journal, article title, volume, issue, page numbers, DOI and the link to the definitive published version) should be maintained. Copyright notices and disclaimers must not be deleted.
- Where content in the article is identified as belonging to a third party, it is the obligation of the user to ensure that any reuse complies with the copyright policies of the owner of that content.
Please note that any file labeled “Source Data”, “Dataset” or “Resource” is released under a Creative Commons CC0 1.0 Universal Licence. This waiver removes legal barriers to the re-use and mining of research data. According to standard scholarly practice, it is recommended to provide appropriate citation and attribution whenever technically possible.